This morning Oxford Nanopore (LSE: ONT) reported FY21 results, with group revenue surpassing company guidance, and gross margins increasing as customers start ramping up their use of acquired instruments. While Oxford Nanopore expects a significant decline in Covid sequencing revenue, the company has nevertheless improved their FY22 outlook.
"Investors will be paying close attention to the continued customer base growth, potential for additional population genomics studies, continued accuracy and cost improvements, and the establishment of Oxford Nanopore’s Diagnostics team in an effort to bring this technology closer to the patient," noted Sebastian Skeet, senior analyst covering the global healthcare sector at Third Bridge.
Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.
Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.
Free 28 day trial. Cancel anytime.
Log In or Sign Up to Armchair Trader+Already a member? Log in here:
Not a member? Sign up now or see the membership benefits
Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.
